
|Articles|June 1, 2001
Clinical trial indicates role for imiquimod as cancer therapy
Topical immune response modifier offers potential in treating skin cancers and precancerous lesions
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
Top 5 Articles of the Week: December 7-12
4
Dermatology Times Spot Test: December 14, 2025
5


















